$MAIA
MAIA Biotechnology, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022023956 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.802M $1.653M $1.166M
YoY Change 41.75%
% of Gross Profit
Research & Development $2.393M $2.343M $1.073M
YoY Change 159.39% 118.39%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.195M $2.343M $2.239M
YoY Change 415.47% 4.65%
Operating Profit -$3.996M -$2.233M
YoY Change 78.94%
Interest Expense -$4.530K $1.716K -$589.7K
YoY Change -107.44% -100.29%
% of Operating Profit
Other Income/Expense, Net $53.80K $65.11K -$450.6K
YoY Change -104.1% -114.45%
Pretax Income -$4.146M -$3.932M -$6.898M
YoY Change 486.27% -42.99%
Income Tax
% Of Pretax Income
Net Earnings -$4.146M -$3.932M -$6.891M
YoY Change 486.27% -42.93%
Net Earnings / Revenue
Basic Earnings Per Share -$0.49 -$1.02
Diluted Earnings Per Share -$0.38 -$0.49 -$647.9K
COMMON SHARES
Basic Shares Outstanding 10.95M 10.94M 5.119M
Diluted Shares Outstanding 10.17M 5.119M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.95M $14.06M $10.95M
YoY Change 3.56% 28.41%
Cash & Equivalents $0.00 $0.00 $10.95M
Short-Term Investments
Other Short-Term Assets $554.3K $460.9K $84.34K
YoY Change 464.48% 446.5%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.81M $14.78M $11.04M
YoY Change 10.64% 33.91%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.800K $2.800K $520.6K
YoY Change -10.31% -99.46%
Total Long-Term Assets $214.0K $2.800K $520.7K
YoY Change -67.31% -99.46%
TOTAL ASSETS
Total Short-Term Assets $11.81M $14.78M $11.04M
Total Long-Term Assets $214.0K $2.800K $520.7K
Total Assets $12.02M $14.78M $11.56M
YoY Change 6.13% 27.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.166M $1.019M $497.3K
YoY Change 21.36% 104.95%
Accrued Expenses $2.103M $1.437M $655.6K
YoY Change 77.41% 119.23%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $48.61K
YoY Change
Total Short-Term Liabilities $3.269M $2.456M $1.313M
YoY Change 52.33% 87.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $13.89K
YoY Change -100.0%
Other Long-Term Liabilities $245.3K $215.7K $0.00
YoY Change
Total Long-Term Liabilities $245.3K $0.00 $13.89K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.269M $2.456M $1.313M
Total Long-Term Liabilities $245.3K $0.00 $13.89K
Total Liabilities $3.514M $2.456M $1.327M
YoY Change 63.76% 85.16%
SHAREHOLDERS EQUITY
Retained Earnings -$44.21M -$39.09M
YoY Change 55.45%
Common Stock $1.096K $1.095K
YoY Change 44.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $8.508M $12.33M $10.23M
YoY Change
Total Liabilities & Shareholders Equity $12.02M $14.78M $11.56M
YoY Change 6.13% 27.91%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$4.146M -$3.932M -$6.891M
YoY Change 486.27% -42.93%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.509M -$4.319M -$2.262M
YoY Change 56.13% 90.92%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.366M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -633.3K 10.26M 10.38M
YoY Change -151.53% -1.12%
NET CHANGE
Cash From Operating Activities -2.509M -4.319M -2.262M
Cash From Investing Activities
Cash From Financing Activities -633.3K 10.26M 10.38M
Net Change In Cash -3.143M 5.940M 8.113M
YoY Change 730.9% -26.78%
FREE CASH FLOW
Cash From Operating Activities -$2.509M -$4.319M -$2.262M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001878313
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Deferred Costs
DeferredCosts
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41455
dei Entity Registrant Name
EntityRegistrantName
MAIA BIOTECHNOLOGY, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1495913
dei Entity Address Address Line1
EntityAddressAddressLine1
444 West Lake Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1700
dei Entity Address City Or Town
EntityAddressCityOrTown
Chicago
dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
06060
dei City Area Code
CityAreaCode
312
dei Local Phone Number
LocalPhoneNumber
416-8592
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
MAIA
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10945904
CY2022Q3 us-gaap Cash
Cash
14063642
CY2021Q4 us-gaap Cash
Cash
10574292
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
460917
CY2021Q4 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
43666
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
54537
CY2022Q3 maia Research And Development Incentives Receivable
ResearchAndDevelopmentIncentivesReceivable
255306
CY2022Q3 us-gaap Assets Current
AssetsCurrent
14779865
CY2021Q4 us-gaap Assets Current
AssetsCurrent
10672495
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4668635
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
651582
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2800
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3122
CY2022Q3 us-gaap Assets
Assets
14782665
CY2021Q4 us-gaap Assets
Assets
11327199
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1019093
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
960401
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1437200
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1185595
CY2022Q3 us-gaap Liabilities
Liabilities
2456293
CY2021Q4 us-gaap Liabilities
Liabilities
2145996
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
70000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10945904
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10945904
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7584980
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7584980
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
1095
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
758
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
51467127
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
37618438
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39090204
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28437993
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-51646
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12326372
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9181203
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14782665
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11327199
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2343154
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1081705
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6539948
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1988450
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1653072
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1151542
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4341880
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2798766
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4668635
CY2022Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
3996226
maia Subscription Receivable For Issuance Of Common Stock
SubscriptionReceivableForIssuanceOfCommonStock
-320000
CY2021Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2233247
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
10881828
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
4787216
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3996226
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2233247
us-gaap Operating Income Loss
OperatingIncomeLoss
-10881828
us-gaap Operating Income Loss
OperatingIncomeLoss
-4787216
CY2022Q3 us-gaap Interest Expense
InterestExpense
1716
CY2021Q3 us-gaap Interest Expense
InterestExpense
451306
us-gaap Interest Expense
InterestExpense
1820
us-gaap Interest Expense
InterestExpense
827539
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
348
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
708
us-gaap Investment Income Interest
InvestmentIncomeInterest
1249
us-gaap Investment Income Interest
InvestmentIncomeInterest
1501
CY2022Q3 maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
65111
maia Australian Research And Development Incentives
AustralianResearchAndDevelopmentIncentives
230188
CY2021Q3 maia Change In Fair Value Of Embedded Features
ChangeInFairValueOfEmbeddedFeatures
96000
maia Change In Fair Value Of Embedded Features
ChangeInFairValueOfEmbeddedFeatures
203000
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
100780
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1546280
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2322943
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2322943
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
63743
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-2970321
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
229617
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-4898261
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3932483
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-5203568
us-gaap Profit Loss
ProfitLoss
-10652211
us-gaap Profit Loss
ProfitLoss
-9685477
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7130
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-74331
maia Deemed Dividend On Warrant Modification
DeemedDividendOnWarrantModification
-450578
CY2022Q3 maia Deemed Dividend For Shares Issued
DeemedDividendForSharesIssued
-1099360
maia Deemed Dividend For Shares Issued
DeemedDividendForSharesIssued
-1099360
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5031843
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5196438
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12202149
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9611146
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.06
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10165622
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10165622
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5119121
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5119121
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8713570
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8713570
maia Options Issued For Accrued Bonus
OptionsIssuedForAccruedBonus
786531
CY2021Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
11001274
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5031843
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5196438
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12202149
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9611146
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-47501
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-51646
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5079344
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5196438
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12253795
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9611146
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9181203
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
47700
CY2022Q1 maia Issuance Of Common Shares Upon Exercise Of Warrants
IssuanceOfCommonSharesUponExerciseOfWarrants
110000
CY2022Q1 maia Issuance Of Common Shares In Connection With Equity Financing
IssuanceOfCommonSharesInConnectionWithEquityFinancing
2373561
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
713330
CY2022Q1 maia Modification Of Warrant In Equity
ModificationOfWarrantInEquity
450578
CY2022Q1 maia Adjustments Additional Paid In Capital Deemed Dividend Modification Of Warrant
AdjustmentsAdditionalPaidInCapitalDeemedDividendModificationOfWarrant
-450578
CY2022Q1 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
1721
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-3413845
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
9013670
CY2022Q2 maia Issuance Of Common Shares Upon Exercise Of Warrants
IssuanceOfCommonSharesUponExerciseOfWarrants
275400
CY2022Q2 maia Issuance Of Common Shares In Connection With Equity Financing
IssuanceOfCommonSharesInConnectionWithEquityFinancing
99999
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
584768
CY2022Q2 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-5866
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-3305883
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6662088
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2022Q3 maia Stock Issued During Period Value Warrants To Underwiter
StockIssuedDuringPeriodValueWarrantsToUnderwiter
343735
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
532438
CY2022Q3 maia Adjustments Additional Paid In Capital Deemed Dividend For Shares
AdjustmentsAdditionalPaidInCapitalDeemedDividendForShares
-1099360
CY2022Q3 maia Foreign Currency Translation Adjustment
ForeignCurrencyTranslationAdjustment
-47501
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-3932483
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
12326372
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1616300
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
27500
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
1
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5400
CY2021Q1 maia Receipt Of Stock Subscription Receivable
ReceiptOfStockSubscriptionReceivable
2002
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
408608
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-1525585
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2581292
CY2021Q2 maia Issuance Of Stock Options To Satisfy Accrued Bonus
IssuanceOfStockOptionsToSatisfyAccruedBonus
786531
CY2021Q2 maia Issuance Of Stock Options To Satisfy Deferred Compensation
IssuanceOfStockOptionsToSatisfyDeferredCompensation
285418
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
660048
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-2956324
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-3688535
CY2021Q3 maia Stock Issued During Period Value Conversion Of Safe
StockIssuedDuringPeriodValueConversionOfSafe
25000
maia Previously Paid Issuance Costs In Connection With The Initial Public Offering
PreviouslyPaidIssuanceCostsInConnectionWithTheInitialPublicOffering
651582
CY2021Q3 maia Issuance Of Common Shares In Connection With Equity Financing
IssuanceOfCommonSharesInConnectionWithEquityFinancing
5484503
maia Options Issued For Deferred Compensation
OptionsIssuedForDeferredCompensation
285418
CY2021Q3 maia Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
1952000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
746253
CY2021Q3 maia Transaction Costs Incurred In Connection With Equity Financing
TransactionCostsIncurredInConnectionWithEquityFinancing
-118332
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-5203568
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
10230886
us-gaap Profit Loss
ProfitLoss
-10652211
us-gaap Profit Loss
ProfitLoss
-9685477
us-gaap Share Based Compensation
ShareBasedCompensation
1830536
us-gaap Share Based Compensation
ShareBasedCompensation
2108868
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2322943
maia Gain Loss On Settlement Of Bonus
GainLossOnSettlementOfBonus
-6531
maia Change In Fair Value Of Embedded Features
ChangeInFairValueOfEmbeddedFeatures
203000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1546280
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
596954
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
412124
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1290
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
230188
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-322
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
520648
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
64788
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
342369
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
252487
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
344940
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-7037
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-226909
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9146390
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2515658
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
7369000
maia Proceeds From Paycheck Protection Program Loan
ProceedsFromPaycheckProtectionProgramLoan
62500
maia Proceeds From Collection Of Subscription Receivable
ProceedsFromCollectionOfSubscriptionReceivable
2002
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2473560
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5366170
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
65700
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5400
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
385400
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
11500000
maia Payment Of Initial Public Offering Transaction Costs
PaymentOfInitialPublicOfferingTransactionCosts
1754586
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
367
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12670074
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12804705
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-34334
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3489350
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10289047
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10574292
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
663457
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14063642
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10952504
maia Conversion Of Convertible Notes And Accrued Interest Into Common Stock
ConversionOfConvertibleNotesAndAccruedInterestIntoCommonStock
8249587
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
25000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
16888
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.82
maia Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
1952000
maia Issuance Of Convertible Note For Payment On Loan To Officer
IssuanceOfConvertibleNoteForPaymentOnLoanToOfficer
-21000
maia Warrants Issued To Underwriters In Connection With The Initial Public Offering
WarrantsIssuedToUnderwritersInConnectionWithTheInitialPublicOffering
343735
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-08-03
us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
minority stockholder of THIO received one share of MAIA common stock for each share of THIO common stock owned prior to the merger.
us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1
CY2022Q3 maia Working Capital
WorkingCapital
12323572
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-39090204
CY2022Q3 us-gaap Cash
Cash
14063642
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2456293
us-gaap Revenues
Revenues
0
CY2022Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
263729
CY2022Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
9
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2373561
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
11111
CY2022Q2 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
9
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
99999
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassification</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain 2021 amounts have been reclassified to conform to the 2022 presentation.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of the Company’s unaudited interim condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The most significant estimates in the Company’s financial statements relate to the valuation of common stock, stock options and warrants, the embedded features in convertible notes, accruals for outsourced research and development activities, and the valuation allowance of deferred tax assets. These estimates and assumptions are based on current facts, historical experience and various other factors believed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span></p>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0
CY2022Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
781647
CY2021Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
384750
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
70922
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
380277
CY2022Q3 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
514676
CY2021Q4 maia Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
268140
CY2022Q3 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
32594
CY2021Q4 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
111271
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
37361
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41157
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1437200
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1185595
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2373561
CY2022Q1 maia Transaction Costs
TransactionCosts
0
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
99999
CY2022Q2 maia Transaction Costs
TransactionCosts
0
CY2022Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.00
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9100000
CY2022Q2 maia Warrants Exercised Shares
WarrantsExercisedShares
394501
CY2022Q2 maia Cashless Exercise At Fair Market Value Per Share
CashlessExerciseAtFairMarketValuePerShare
9
CY2022Q2 maia Issuance Of Common Shares Upon Cashless Exercise Of Warrants Shares
IssuanceOfCommonSharesUponCashlessExerciseOfWarrantsShares
315601
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
6.25
CY2022Q3 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2023-01-23
CY2022Q3 maia Class Of Warrant Or Right Date From Which Warrants Or Rights Expire
ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExpire
2027-07-27
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1311117
CY2021Q4 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
4.03
CY2021 maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P7Y3M18D
maia Class Of Warrants Issued
ClassOfWarrantsIssued
115000
maia Class Of Warrants Weighted Average Exercise Price Issued
ClassOfWarrantsWeightedAverageExercisePriceIssued
6.25
maia Class Of Warrants Exercised
ClassOfWarrantsExercised
608612
maia Class Of Warrants Weighted Average Exercise Price Exercised
ClassOfWarrantsWeightedAverageExercisePriceExercised
1.80
maia Class Of Warrants Expired
ClassOfWarrantsExpired
20520
maia Class Of Warrants Weighted Average Exercise Price Expired
ClassOfWarrantsWeightedAverageExercisePriceExpired
5.00
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
796985
CY2022Q3 maia Class Of Warrants Weighted Average Exercise Price
ClassOfWarrantsWeightedAverageExercisePrice
6.03
maia Class Of Warrants Weighted Average Remaining Contractual Term
ClassOfWarrantsWeightedAverageRemainingContractualTerm
P5Y4M28D
maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Percentage Of Shares Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsPercentageOfSharesGranted
0.10
maia Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePricePercentage
1.10
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5797185
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.22
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M2D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
768113
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.84
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
36500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.80
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6511910
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.53
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M2D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
8536318
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5443036
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.19
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y9M25D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7664470
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
532438
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
778544
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1830536
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2108868
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0

Files In Submission

Name View Source Status
maia-20220930_pre.xml Edgar Link unprocessable
0000950170-22-023956-index-headers.html Edgar Link pending
0000950170-22-023956-index.html Edgar Link pending
0000950170-22-023956.txt Edgar Link pending
0000950170-22-023956-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
maia-20220930.htm Edgar Link pending
maia-20220930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
maia-20220930_cal.xml Edgar Link unprocessable
maia-20220930_def.xml Edgar Link unprocessable
maia-20220930_lab.xml Edgar Link unprocessable
maia-20220930_htm.xml Edgar Link completed
maia-ex31_1.htm Edgar Link pending
maia-ex31_2.htm Edgar Link pending
maia-ex32_1.htm Edgar Link pending
maia-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending